The tumor-promoting effects produced were abrogated by administration of specific antibodies to IL-10, or by administration of a σ1R antagonist, indicating that σ1R agonist ligands augment tumor growth via a cytokine-dependent, receptor-mediated mechanism that involves regulation of T helper1/T helper2 cytokine balance (1071). The gene discussed is IL10; the disease is neoplasm.